Breast cancer vaccine - Stressgen

Drug Profile

Breast cancer vaccine - Stressgen

Latest Information Update: 03 Jul 2001

Price : $50

At a glance

  • Originator Nventa Biopharmaceuticals Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 03 Jul 2001 Discontinued-Preclinical for Breast cancer in Canada (Unknown route)
  • 25 Jun 2001 No-Development-Reported for Breast cancer in Canada (Unknown route)
  • 20 Feb 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top